Last updated: Jul 12, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07142967 | — | Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II) | Androgen receptor -- antagonist (ADT); Unknown mechanism (MR-Linac-guided radiotherapy) |
| NCT05616650 | 2 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | Unknown mechanism |
| NCT05800665 | 1 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | Unknown mechanism |
| NCT06910657 | 1 | IDOV-Immune for Advanced Solid Tumors | Oncolytic vaccinia virus -- oncolytic virus therapy (IDOV-Immune) |
| NCT07048314 | 1, 2 | Stem Cells for Erectile Dysfunction Post RALP | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| University Health Network, Toronto | 20 |
| Mayo Clinic | 16 |
| National Cancer Institute (NCI) | 15 |
| Memorial Sloan Kettering Cancer Center | 15 |
| M.D. Anderson Cancer Center | 15 |
Countries/regions with the most active trial sites for prostate cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Mar 2028 | NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | Prostate-specific membrane antigen (PSMA) -- radioligand therapy with lutetium-177 labeled PSMA ligand |
| Aug 1, 2026 | NCT07682649 | Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Prostate-specific membrane antigen (PSMA) -- radioligand therapy (radiolabeled small molecule) |
| Jul 15, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | CXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor) |
| Jul 15, 2026 | NCT07674771 | Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery | PSMA -- radiolabeled ligand for PET imaging and targeted radiotherapy |
| Jul 7, 2026 | NCT07543055 | A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread | PSCA -- chimeric antigen receptor T-cell therapy (CAR-T) |
| Jul 1, 2026 | NCT06906471 | A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | PSMA -- fluorescent histopathology agent |
| Jul 2026 | NCT07581184 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | PSMA -- targeted alpha-particle radioligand therapy |
| Jul 2026 | NCT07683013 | Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer | Androgen receptor -- antagonist (AR inhibitor) |
You've seen the prostate cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.